Blockchain in the pharmaceutical industry for verifiable traceability

The pharmaceutical industry does not merely move boxes. Before dispensing come active ingredients, materials, manufacturing batches, quality controls, release by authorized personnel, packaging, wholesale distribution and storage. Each stage produces evidence that must be linked to the correct product and retained for the regulatory period.

Manufacturers, marketing-authorization holders, logistics operators, wholesalers, pharmacies, hospitals and authorities participate in the commercial chain. A pack may change ownership without changing custody, be aggregated into a case or pallet and later disaggregated. Returns, recalls and exceptions create routes that are not linear. Useful traceability must represent those states, not merely a list of locations.

Blockchain fits where independent organizations need to share verifiable events without reconstructing history from email, portals and reconciliations. Marketing authorization, batch release and a trading partner's legitimacy nevertheless come from regulatory systems and external controls. The network distributes evidence; it does not by itself make a product safe, effective or lawful to market.

In pharma, blockchain works as a layer of traceability and verification. Each pack receives a unique identifier through serialization. Manufacturing, transport, distribution and dispensing then produce verifiable events that authorized participants can share, while regulated repositories and quality systems retain their separate roles.

An authorized query can check declared status and reconstruct the journey that was actually captured. It does not independently establish that the product is authentic, safe or complete. Sensitive trial and patient data normally remains off-chain; a fingerprint can reveal later changes but cannot guarantee the quality or truth of the source data.

Blockchain provides shared state when manufacturers, logistics operators, wholesalers, pharmacies and authorities must verify a medicine's identity and status. Each participant records events within its responsibility. The network orders manufacture, transfer, return, recall and dispensing, while regulatory repositories and quality systems retain their authority over the underlying decisions.

Traditional infrastructure has each company exchange messages with repositories and partners, then reconstruct exceptions from separate copies. A blockchain network lets them verify common state and its sequence of changes. It does not replace serialization or pharmaceutical rules, but can reduce reconciliation when several participants genuinely need shared control over history.

Serialization assigns a unique identity to each pack. Verification checks that identity and status against an authorized repository. Tracing reconstructs the events explaining how it arrived. A system may serialize and verify at dispensing without sharing the entire journey; it may also trace batches without identifying every unit. Architecture must respond to the regulatory requirement and specific risk.

Aggregation links packs to cases and pallets so operators do not scan every unit at every movement. If a case is opened or its contents change, the relationship must be updated. Errors in that hierarchy cause false alerts or leave units outside the history even when the network works correctly.

EPCIS provides a model for describing what happened, when, where, why and to which object. DLT can distribute those events and their proof among partners, but it should not reinvent industry identifiers or vocabulary. Without common standards, every node retains a technically immutable yet semantically incompatible version.

In 2017, WHO estimated that close to one in ten medicines in low- and middle-income countries was substandard or falsified, with annual spending of approximately $30.5 billion. Its 2024 fact sheet repeats those estimates. They measure neither total global economic harm nor savings that can be attributed to blockchain.

The response combines regulation, package identification and collaboration between organisations. US DSCSA establishes interoperable exchange obligations; in Europe, EMVS verifies medicine identifiers through connected repositories. In December 2025, EMVO reported coverage across 30 countries and 125,000 end users. That provides an operational scale benchmark for comparing solutions, rather than a measure of blockchain adoption.

The European verification system uses centralized repositories and verifies packs at scale. A blockchain network offers a different governance model where multiple companies need to share state and evidence without granting exclusive control to one participant. That requirement should be demonstrated before adding distributed infrastructure and its operational complexity.

A normal journey is the easy part. A saleable return requires evidence that the pack is authentic, came from an authorized partner, was not dispensed or recalled and remained under acceptable conditions. An alert may affect a batch, serial range, market or date. The system must locate units without indiscriminately blocking legitimate product.

A shared record reduces bilateral inquiries and propagates status, but it needs conflict rules. Two actors may report incompatible events, a scanner may work offline or a partner may submit data late. The answer is not to erase history but to add the correction, identify responsibility and determine which state has operational effect.

Recall speed also depends on events being complete and linked to physical inventory. Recording every transfer does not guarantee that a pharmacy can find the box or that the patient receives an alert. Blockchain improves investigation and coordination; procedures, directories and communication channels complete the response.

For a commercial return, checking that an identifier exists is only the beginning. The wholesaler needs to verify package status, its relationship to the shipment and the conditions permitting restocking. An alert may reflect a scanning error or a situation requiring investigation. The system should retain the reason, supporting evidence and accountable decision-maker without turning a technical match into automatic authorisation to resell the medicine. This separates identifier verification from the broader quality and operational judgement needed to handle the returned product.

A recall requires locating packs or batches, communicating instructions and confirming action at each point in the supply chain. Distinguish receipt of the notice, stock blocking and confirmation of physical withdrawal. A node may have received the event while warehouse staff still need to act. Evaluation should measure that gap and include disconnected participants or incomplete records. The process ends with reconciliation of quantities and exceptions, alongside notification history. Treating message delivery as successful withdrawal would overstate what the infrastructure has actually achieved.

Biologics, vaccines and advanced therapies may lose quality when temperature or other conditions leave the permitted range. Sensors and loggers provide readings; the network can seal them, associate them with the shipment and expose a breach to manufacturers, carriers and recipients.

On-chain integrity does not establish that a sensor was calibrated, attached to the correct package or protected from tampering. The design must also decide how thousands of readings are summarized, who assesses an excursion and what happens without connectivity. A contract may trigger an alert or hold payment; product release remains governed by quality procedures and authorized personnel.

A rigorous system preserves the original reading, device identity, calibration, location and chain of custody. Thresholds are versioned and exceptions leave evidence. Automation can then accelerate investigation without turning one data point into an automatic regulatory conclusion.

A trial distributes responsibility among the sponsor, sites, investigators, CROs, laboratories, ethics committees and regulators. Protocols, consent, case-report forms, analyses and decisions are versioned over years. Anchoring document and event fingerprints can establish sequence and reveal later modification without publishing sensitive content.

Proof of integrity does not establish that the data is clinically correct or the trial followed its protocol. An observation may be transcribed incorrectly, a device may fail or a correction may be legitimate. The system must preserve source data, reason for change, signature and the audit trail required by GxP. Immutable does not mean never corrected; it means correction does not hide the prior version.

Consent and privacy require specific design. Withdrawal does not necessarily erase data already processed under regulatory duties, but may prevent future uses under the applicable framework. The network can record which version was accepted and when permission changed; the controller still determines legal basis, access, pseudonymization and retention. Codes capable of being linked to a person should not be treated as anonymous merely because they are hashed.

The strongest use cases combine identified products, authorized participants and regulated events. Serialization, returns, recalls, cold-chain monitoring, clinical trials and material provenance require different evidence. Blockchain coordinates the state several companies must verify, while manufacturing, quality control, batch release and dispensing remain under their established systems and accountable professionals.

Partners do not need to see all of one another's commercial information. Prices, volumes, suppliers and routes may be confidential even where a regulator must reconstruct the chain. A pharmaceutical network usually needs role-based permissions, private channels or selective proofs, together with clear policies on visible metadata.

Governance determines who admits a partner, validates licenses, operates nodes, changes rules and responds to a vulnerability. It must also handle late data, disputes, mergers and participant exit. A consortium does not remove an operator; it distributes selected functions under a common agreement.

Liability remains attached to the regulated act. The manufacturer releases the batch, the wholesaler retains its duties and the pharmacy decides dispensing under applicable law. Technical consensus can prove what was declared, but it does not automatically reallocate those responsibilities.

ERP, warehouse systems, serialization platforms, regulatory repositories and devices already run the operation. DLT receives standardized events, maintains shared states and provides evidence to authorized partners. Integration should be idempotent to avoid duplicates and preserve the link between the on-chain event and its source document.

Personal data and detailed GxP documents normally stay off-chain under retention and access controls. The network stores identifiers, states or fingerprints where shared verification has a purpose. Encryption alone does not solve retention. Immutable encrypted data may become exposed if its key is compromised in the future.

Continuity requires offline queues, reconciliation, key rotation and a migration procedure. A pharmacy or warehouse cannot stop because one node is unavailable. The system must degrade safely and distinguish temporary lack of confirmation from illegitimate product.

The best proof does not attempt to reconstruct the entire global chain. It may focus on saleable returns, batch investigation, one cold-chain route or event exchange within a defined group. The baseline is measured and data, responsibilities and alternatives are identified before choosing technology.

Relevant metrics include verification time, event completeness, false positives, recall speed, reconciliations avoided and cost per partner. Transaction or node count does not establish value. The project must also measure onboarding time for a small participant and how many exceptions require manual work.

Scaling depends more on standards and governance than raw chain throughput. If every onboarding requires a different integration or bilateral agreement, the network reproduces existing fragmentation. DLT is justified when shared state reduces disputes or dependency without creating infrastructure more expensive than the problem.

Most cost lies not in creating an identifier but in resolving exceptions. A suspect batch mobilizes quality staff, warehouses, trading partners and authorities; a return requires custody reconstruction; a temperature discrepancy holds inventory until release is decided. When each party holds incompatible evidence, time is spent finding and reconciling documents.

Shared state can reduce that investigation, but it adds integration, node, governance, support and partner-validation costs. The economic case compares avoided time and reduced risk with total cost over years. Seconds saved on a query do not justify complex infrastructure if exceptions are still handled by email and telephone.

Incentives also differ. A manufacturer may value brand protection; a wholesaler, faster returns; a pharmacy, simple verification; and an authority, complete evidence. Governance must allocate costs and benefits so every party has reason to submit quality data. Otherwise some participants bear the burden while others capture the value.

Drug traceability is regulated. In the US, DSCSA requires electronic, interoperable package-level exchange among authorized trading partners; FDA recommends standards such as GS1 EPCIS, but the law does not prescribe a blockchain. In the EU, the Falsified Medicines Directive and EMVS impose different identification and verification duties.

Clinical trials sit under GDPR, the Clinical Trials Regulation and GCP and GxP requirements. Keeping content off-chain reduces exposure, but a linkable fingerprint, key or metadata may still be personal data. Legal basis, purpose, minimization, retention, rights and accountability must be resolved before the technical design.

Technology does not replace repositories or checks required in each jurisdiction. In the United States, DSCSA establishes electronic, interoperable package-level exchange among authorized trading partners. In the European Union, EMVS verifies identifiers at dispensing through connected repositories and does not use blockchain. DLT must integrate with those obligations or address an additional process; presenting it as a parallel alternative creates duplication and risk.

GxP rules require validated systems, change control, integrity, availability and audit trails. Contract code, nodes and interfaces enter the quality perimeter when they support a regulated decision. Accountable parties, testing, supplier management and continuity are required. Cryptographic resistance to change does not by itself establish that a system is validated for its intended use.

A central database is sufficient where there is an accepted operator, a stable perimeter and confidence in its ability to govern data and change. EMVS shows that repository architecture can verify packs at scale without blockchain. Adding nodes does not improve the outcome when everyone still depends on one authority and has no need to share control.

DLT is more defensible when a process crosses companies or jurisdictions, parties need to retain their own evidence and state must survive operator changes. Returns, ingredient provenance, custody of high-value therapies or exception investigations may benefit from common history where several reconciliations are currently required.

The decision compares governance, privacy, availability, performance, integration cost and exit. It also asks who executes a correction and which system prevails in conflict. The right choice is the smallest architecture satisfying traceability and regulatory control. Using blockchain merely to replicate an existing repository adds complexity without distributing trust in a useful way.

The network can preserve and share events, but medicine safety still depends on manufacturing, quality, identity and physical controls. It cannot independently detect a counterfeit carrying a copied legitimate identifier, a manipulated reading or an uncaptured temperature excursion. Digital evidence remains only as reliable as its source and capture process.

These concepts distinguish package identity, status verification, logistics history and regulatory compliance. They also clarify the role of GS1 and EPCIS as a common language beside the ledger used to share events. Understanding them prevents serialization becoming traceability, a fingerprint becoming the full document or technical consensus becoming pharmaceutical release.